Gene Therapies for Sickle Cell Disease.
- Published in:
- Journal of Pharmacy Technology, 2024, v. 40, n. 5, p. 236, doi. 10.1177/87551225241268742
- By:
- Publication type:
- Article
Works matching IS 87551225 AND DT 2024 AND VI 40 AND IP 5
Results: 6
1
2
A Review of the Potential Role of Sotagliflozin: A Dual SGLT2 and SGLT1 Inhibitor—in the Treatment of Heart Failure.
- Published in:
- Journal of Pharmacy Technology, 2024, v. 40, n. 5, p. 248, doi. 10.1177/87551225241261040
- By:
- Publication type:
- Article
3
Gepirone: A New Extended-Release Oral Selective Serotonin Receptor Agonist for Major Depressive Disorder.
- Published in:
- Journal of Pharmacy Technology, 2024, v. 40, n. 5, p. 230, doi. 10.1177/87551225241269179
- By:
- Publication type:
- Article
4
Retrospective Evaluation of Inpatient Warfarin Management Practices in Patients Immediately Following Left Ventricular Assist Device Implantation.
- Published in:
- Journal of Pharmacy Technology, 2024, v. 40, n. 5, p. 215, doi. 10.1177/87551225241268759
- By:
- Publication type:
- Article
5
Utilization of Glucagon-Like Peptide-1 Receptor Agonist and Dipeptidyl Peptidase-4 Inhibitors at the Veterans Health Administration.
- Published in:
- Journal of Pharmacy Technology, 2024, v. 40, n. 5, p. 223, doi. 10.1177/87551225241266773
- By:
- Publication type:
- Article
6
Pharmacovigilance of Radiopharmaceuticals: Challenges and Opportunities.
- Published in:
- Journal of Pharmacy Technology, 2024, v. 40, n. 5, p. 257, doi. 10.1177/87551225241266172
- By:
- Publication type:
- Article